Caring for Patients Treated With ICIs: Guidance and Resources for Nurses and Pharmacists

Caring for Patients Treated With ICIs: Guidance and Resources for Nurses and Pharmacists

Monday, June 22, 2020
Webinar -- 7:00 PM ET
http://www.clinicaloptions.com/Nursing2020irAEJoin3

Agenda

Introduction – John A. Thompson, MD (5 min)

Cancer Immunotherapy: An Overview – John A. Thompson, MD (10 min)

  • Review of the current therapeutic landscape and best practices for immune checkpoint inhibitors in oncology
  • Professional resources for oncology clinicians during COVID-19

Case-Based Applications and Guidance for Multidisciplinary irAE Management – Marianne Davies, DNP, CNS, ACNP-BC, AOCNP (20 min)

  • Differentiating irAE-related toxicities from other etiologies including viral infection and strategies for optimal management
  • Educating patients to recognize and report irAEs and counseling on expectations of cancer care during COVID-19

Clinical Pearls for the Care of Patients on Cancer Immunotherapy – Marianne Davies, DNP, CNS, ACNP-BC, AOCNP (15 min)

Question and Answer Session (10 min)

Faculty

Program Director
John Thompson, MD

Professor of Medicine
Division of Medical Oncology
University of Washington
Seattle, Washington

Faculty
Marianne Davies, DNP, CNS, ACNP-BC, AOCNP

Associate Instructor
Adult Specialty Program
Yale University School of Nursing
Nurse Practitioner
Medical Oncology
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate new agents and recent findings into the treatment of patients with cancer who are eligible for treatment with immune checkpoint inhibitors.

Target Audience
This program is intended for oncology nurses and other healthcare providers who care for patients with cancer using immunotherapies.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the different immune checkpoint inhibitors and their current indications for the treatment of patients with cancer
  • Understand the unique spectrum of adverse events associated with different immune checkpoint inhibitors based on their mechanism of action
  • Communicate with and educate patients to actively monitor and report symptoms that are associated with cancer immunotherapy and an activated immune system
  • Assess if and when it is appropriate to withhold, discontinue, and/or resume immune checkpoint inhibitor therapy in the setting of an immune-related adverse event
  • Collaborate effectively with colleagues from oncology and nononcology specialties who may be involved with optimal diagnosis and management of immune-related adverse events
  • Plan approaches and care pathways for detecting and managing irAEs across tumor types

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-048-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.